Nevirapine (Viramune): European WarningMay 5, 2000 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! On April 12 the European Agency for the Evaluation of Medicinal Products (EMEA) issued a warning on risks of severe or life-threatening skin or liver reactions to nevirapine, requiring precautions especially for patients starting the drug, during their first 8 weeks of treatment. The full public statement is available at: http://www.eudra.org/humandocs/PDFs/PS/1126000EN.pdf In the U.S., some but not all of this information is already in the drug labeling, and new data from clinical trials is being analyzed to fine-tune any additional warnings required.
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
|
|